Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

INTRODUCTION: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Knappskog, Stian, Chrisanthar, Ranjan, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Leirvaag, Beryl, Miletic, Hrvoje, Lønning, Per E
Formáid: Artigo
Teanga:Inglês
Foilsithe: BioMed Central 2012
Ábhair:
Research Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3446381/
https://ncbi.nlm.nih.gov/pubmed/22420423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3147
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla